| CARVIEW |
Doing now what patients need next
:quality(90)/)
We are Roche
A healthier future. It’s what drives us to innovate.
To continuously advance science and ensure everyone has access to the healthcare they need today and for generations to come.
Creating a world where we all have more time with the people we love.
That’s what makes us Roche.
In the spotlight
:quality(90)/)
:quality(90)/)
For Investors
Discover great stories aboutSciencePartnershipCulturePatientsSociety
Perspectives and powerful moments that shape healthcare.
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
We will prevent diseases by identifying high-risk patients early to enable timely use of medicines.
:quality(90)/)
We will stop diseases by accurately diagnosing and stratifying patients to halt disease progression through targeted medicines.
:quality(90)/)
We will cure diseases by identifying the cause of disease in order to restore health through curative medicines.
:quality(90)/)
:quality(90)/)
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
Basel, 22 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ (mosunetuzumab), as a subcutaneous (SC) formulation, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy, based on results from the phase I/II GO29781 study.
:quality(90)/)
Roche Accessibility Statement
At Roche, we are committed to ensuring that our websites and digital resources are accessible to all users.
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)